Skip to main content

MYGN

Stock

MYGN

Stock
Health Care
Diagnostics & Research

Performance overview

MYGN Price
Price Chart

Forward-looking statistics

Beta
1.49
Risk
53.76%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees3K
Market cap$2.0B

Fundamentals

Enterprise value$555.3M
Revenue$831.3M
Revenue per employee—
Profit margin-12.20%
Debt to equity22.36

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.12
Dividend per share$21.00
Revenue per share$9.14
Avg trading volume (30 day)$10M
Avg trading volume (10 day)$7M
Put-call ratio—

Macro factor sensitivity

Growth-0.1
Credit+6.5
Liquidity+0.2
Inflation-2.9
Commodities-0.1
Interest Rates-2.4

Valuation

Dividend yield375.00%
PEG Ratio37.33
Price to sales0.62
P/E Ratio37.33
Enterprise Value to Revenue0.67
Price to book0.73

Upcoming events

Next earnings dayNovember 8, 2024
Next dividend day—
Ex. dividend dayJuly 1, 2009

News

Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?

MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.

Zacks Investment Research (June 16, 2025)
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc's UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics' GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect in the first half of 2025.

Benzinga (February 25, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free